London-based AI life sciences startup Basecamp Research raised a $140M Series C led by S32, with participation from Anthropic, taking its total funding to $225M

The cost to license foundational AI models decreases by up to 50% for life science researchers.

Basecamp Research, a UK-based life sciences startup, has secured $140 million in a Series C funding round. The round was led by S32 and included participation from prominent AI companies Nvidia and Anthropic. This latest investment brings Basecamp Research's total funding to $225 million since its founding in 2019. The company utilizes artificial intelligence and biodiversity data to accelerate the development of new medicines for diseases such as cancer and autoimmune disorders. The significant size of this Series C round highlights investor confidence in AI-driven approaches within the pharmaceutical sector.

This funding round signals a growing trend of significant capital flowing into AI-centric drug discovery platforms, with major AI players like Anthropic and Nvidia taking direct stakes. It suggests these AI giants see tangible opportunities in the life sciences sector beyond providing compute or foundational models as a service, potentially leading to deeper collaborations and integrations. The substantial investment in Basecamp Research underscores the market's increasing validation of AI's potential to revolutionize pharmaceutical R&D timelines and success rates.

The infusion of capital will likely enable Basecamp Research to scale its AI platform and accelerate its drug development pipeline. For other AI-driven biotech startups, this valuation and investor interest set a new benchmark, potentially intensifying competition for talent and resources. It also indicates a shift where AI companies themselves are becoming direct participants and investors in the application of their technology to solve complex scientific challenges, moving beyond a pure vendor-client relationship.